ASCO 2026 | Prof. Xiaotian Zhang and Prof. Yelena Janjigian: The DESTINY-Gastric Program Reshapes HER2-Targeted Therapy in Gastric Cancer as Chinese and U.S. Experts Discuss the Next Chapter

ASCO 2026 | Prof. Xiaotian Zhang and Prof. Yelena Janjigian: The DESTINY-Gastric Program Reshapes HER2-Targeted Therapy in Gastric Cancer as Chinese and U.S. Experts Discuss the Next Chapter

The landmark results of the DESTINY-Gastric04 (DG04) trial have firmly established trastuzumab deruxtecan (T-DXd) as the missing piece in second-line HER2-targeted treatment for gastric cancer. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the DESTINY-Gastric03 (DG03) study was also unveiled, highlighting the promising potential of T-DXd in the first-line setting. As T-DXd moves from later-line therapy toward frontline treatment for HER2-positive gastric cancer, an increasing number of patients stand to benefit.
Precise Characterization of Transplant Prognosis: From DTA Mutation Monitoring to TP53 Aberration Stratification, Experts at EHA 2026 Discuss Changing Landscape of Myeloid Neoplasm Treatment 

Precise Characterization of Transplant Prognosis: From DTA Mutation Monitoring to TP53 Aberration Stratification, Experts at EHA 2026 Discuss Changing Landscape of Myeloid Neoplasm Treatment 

The 2026 European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain. As one of the most influential academic events in the global hematology field, the application of allo-HSCT in myeloid neoplasms remains a focus of academic debate and innovation. This specialized session, chaired by Professor Anna Sureda (Catalan Institute of Oncology, Barcelona, Spain), focused on post-transplant molecular monitoring, refinement of prognostic strategies, and algorithm optimization for refractory cases in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Research teams from China, Switzerland, Sweden, Spain, and other countries shared five milestone academic reports, providing new evidence-based medical grounds for clinical precision transplantation.
EHA 2026 Authoritative Release: Major Update of CLL and Richter Transformation Guidelines, Opening a New Era of Precision and Fixed-Duration Therapy 

EHA 2026 Authoritative Release: Major Update of CLL and Richter Transformation Guidelines, Opening a New Era of Precision and Fixed-Duration Therapy 

At the 2026 European Hematology Association (EHA) Annual Meeting, experts including Professor Paolo Ghia from Università Vita-Salute San Raffaele, Professor Barbara Eichhorst from the University Hospital of Cologne, and Professor Elżbieta Kalicińska from Wroclaw Medical University jointly released and interpreted the latest version of the "EHA Guidelines for the Management of Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)". This update not only incorporates data from multiple cutting-edge targeted studies but also includes "Richter Transformation" in the title for the first time, aiming to provide a more practical clinical pathway for hematologists worldwide.
Breaking the Stalemate in CALR-Mutated Myelofibrosis: INCA033989 Demonstrates Deep Disease-Modifying Potential and Bone Marrow Morphological Improvement 

Breaking the Stalemate in CALR-Mutated Myelofibrosis: INCA033989 Demonstrates Deep Disease-Modifying Potential and Bone Marrow Morphological Improvement 

At the 2026 European Hematology Association (EHA) Annual Congress, Professor Claire Harrison from Guy's and St Thomas' NHS Foundation Trust, London, shared the latest research data on the mutation-specific monoclonal antibody INCA033989 (hereinafter referred to as "989") for the treatment of calreticulin (CALR)-mutated myelofibrosis (MF) patients. This study aims to evaluate the safety, tolerability, and preliminary efficacy of this first-in-class drug in monotherapy and combination regimens, providing a new path for precision treatment in this specific subpopulation of CALR-mutated patients.
Targeting the 8 kPa Prognostic Threshold: EBMT-EHA Thalassemia Gene Therapy Guideline Update Strengthens Precise Liver Risk Assessment 

Targeting the 8 kPa Prognostic Threshold: EBMT-EHA Thalassemia Gene Therapy Guideline Update Strengthens Precise Liver Risk Assessment 

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Giuseppe De Franceschi from the University of Verona, Italy, representing the joint working group of the European Society for Blood and Marrow Transplantation (EBMT) and EHA, delivered an in-depth interpretation of the latest update to the "Guidelines for Patient Selection for Gene Therapy in Transfusion-Dependent β-Thalassemia (TDT)." This guideline update aims to integrate the latest clinical evidence from gene addition and gene editing technologies to provide standardized patient screening and follow-up pathways for hematologists worldwide.